Ellipses Accelerates Cancer Treatment R&D With ‘Unique’ Business Model
Emerging Company Profile: The UK biotech is working to expedite its portfolio of acquired drug candidates for cancer through the clinic before out-licensing to big pharma in a bid to bring patients the treatments they need sooner rather than later.
You may also be interested in...
The French firm’s Q4 sales missed consensus due to a slow-down in its vaccine franchise, while analyst concern regarding a pivotal readout for blockbuster product Dupixent in COPD increased.
Recent executive moves in the industry include C-suite changes at Fresh Tracks Therapeutics and Protara Therapeutics. Meanwhile, new directors were appointed at Grey Wolf Therapeutics and BioSenic.
The UK major’s Jesduvroq has become the first drug of its class to win US approval for anemic kidney disease but significant label restrictions have left some analysts lukewarm on its sales potential.